Scholarships for talented students as an exceptional opportunity to work in a top international business environment

  • Novartis Solids Lendava launched the scholarships in cooperation with  the Faculty of Chemistry and Chemical Technology of the University of Maribor  and the PORA Development Agency Gornja Radgona.
  • The purpose of the staff development scholarship is to retain key  chemical and engineering talent in North East Slovenia.
29. 11. 2021

On Friday, November 26, the Solids Lendava signed a scholarship agreement with first-year students Neja Preložnik and Blaž Vidovič at the Faculty of Chemistry and Chemical Technology of the University of Maribor. The talented students were selected on the basis of a call for applications, which is the result of cooperation with the Faculty of Chemistry and Chemical Technology of the University of Maribor and the PORA Development Agency Gornja Radgona.

The purpose of the cooperation for the staff development scholarship between the partners involved is to retain key chemical and engineering talent in the local area and to show that there are long-term opportunities to be found in North East Slovenia as well. This approach aims to give future graduates the opportunity to integrate into an international environment and learn about working processes in a top international pharmaceutical business environment while they are still studying.

"We believe that by actively engaging students while they are still studying, we can prepare them for one of the next crucial steps in their lives – their first job. The Lendava plant has experienced a remarkable breakthrough in the last decade. We have become a key worldwide supplier for innovative and generic medicines in solid dosage forms for Novartis. Last year, we served patients on every continent with more than 4,000 different end products in more than 150 markets.

 We already employ more than 550 associates.

“We are working towards further breakthroughs and higher value-added production, making us even more attractive to young talent who would otherwise look abroad for education and work. With our excellent work and innovative scholarship scheme, we want to attract young people from our region and beyond to join our young team. We are offering an excellent career path at the "beak" of Slovenia, in Prekmurje, where the world-class international pharmaceutical environment with Industry 4.0 is in close proximity," said Dr. Simon Rečnik, Solids Lendava Site Head, at the signing of the agreement.

Both scholarship holders view the signing of the scholarship agreement as a great opportunity to learn new skills and start a successful career.

"The scholarship will facilitate my studies, help me integrate into the workplace more quickly and ensure financial security during my studies. At a time when young people are finding it more difficult to find employment, I will have the security of a job in an internationally recognized company after completing my studies. During my studies, I will gain additional practical skills, network and gain knowledge from professionals and consolidate the theoretical knowledge acquired at university. The scholarship is an acknowledgement of my work so far and gives me the motivation to continue. I realize that the scholarship is an opportunity that not everyone gets and a great stepping stone to start my career with a company that values knowledge, development and young people. I know that I will achieve the goals I have set for myself, and I am grateful for the trust and the opportunity," said scholarship holder Neja Preložnik on signing the scholarship.

Blaž Vidovič added, "I would like to thank the Novartis Solids Lendava unit for the trust they have placed in me. For me, this scholarship represents a great new motivation to continue my studies, but at the same time, it is a fantastic opportunity to experience work in the pharmaceutical and healthcare industry from the very beginning. This will give me many additional skills during my studies that will help me in my future career. It is a great honor to work with Novartis and I am very optimistic about my future work and studies."

* * *

Novartis  is the leading provider of medicines in Slovenia, where Lek d.d., Novartis Pharma Services Inc.,Podružnica v Sloveniji and Sandoz d.d., operate. Together we are building and maintaining the reputation of a dynamic, ethical, and trusted pharmaceutical company. Lek develops, manufactures, and markets effective, safe, and high quality medicines and active pharmaceutical ingredients. With our knowledge, quality, and experience we have gained an important role in Novartis' organizational structure, especially in the Novartis Technical Operations,Global Drug Development, Novartis Business Services, and the generic division Sandoz. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We invest a great deal in the development, education, and training of our employees. Over the last nine years, the company has created more than 3,350 new job opportunities, making us one of the biggest employers in Slovenia. Novartis invested inSlovenia more than EUR 2.7 billion since 2003.

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2020 sales ofUSD 9.6 billion.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140nationalities work at Novartis around the world. Find out more at

* * *

This press release contains statements and forecasts of future business operations.The forecasts include estimates based on all the information currently available to us. Should these forecasts prove unreliable, the actual results of business operations could be different from those expected.

- end -

For further information, please contact:
Communication and External Affairs
Lek Pharmaceuticals d.d.
Telephone: 01 580 22 43